BIA-Brukerstyrt innovasjonsarena
Development of targeted therapies for mutant RAS cancers
...deal with multiple RAS mutation variants. Targovax´s mutant RAS TG01 vaccine offers exactly...is to further the clinical development of Targovax's mutant RAS TG platform by employing novel...av legemidler mot RAS-mutert kreft. Targovax's neste-generasjon "TG" vaksineteknologi, en...
